Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

argenx to host inaugural R&D day and webcast on September 22, 2016

argenx N.V.
Posted on: 15 Sep 16

Breda, the Netherlands / Ghent, Belgium, 15 September 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it will host its inaugural R&D day on Thursday, September 22, 2016 from 9:00 a.m. -12:00 p.m. ET in New York City.  

During the event, members of argenx management will present updates to the Company's pipeline of differentiated antibodies including ARGX-113 for severe autoimmune diseases and ARGX-110 for oncology indications.

Guest speakers will also present on the treatment landscape and unmet needs in selected argenx indications including;

  • James Howard, Jr., M.D., Chief, Neuromuscular Disorders Section, University of North Carolina, Chapel Hill, North Carolina, USA
  • Adrian Newland, M.D., Professor of Hematology, The Royal London Hospital, London, UK
  • Owen O'Connor, MD, PhD, Director of the Center for Lymphoid Malignancies, Colombia University, New York, USA

A live webcast of the event will be available via this link . The webcast will be archived following the event and available for download on the Company's website at

About argenx
argenx (ARGX) combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.

For further information, please contact:

Joke Comijn, Communications and Investor Relations Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19

Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx' actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

 "Management's Discussion and Analysis of Financial Condition and Results of Operations"

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: argenx N.V. via GlobeNewswire

Last updated on: 16/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.